Marcaine Glucose (Bupivacaine Hydrochloride, Anhydrous)

Bupivacaine hydrochloride blocks voltage‑gated sodium channels on nerve membranes, stabilizing them in an inactive state. This prevents the generation and propagation of action potentials, thereby interrupting nerve signal transmission and producing a regional loss of sensation.

The specific dose of Marcaine Glucose is determined by the prescribing clinician based on the procedure, route of administration, patient weight, and clinical judgment. Dosage recommendations are provided in the product’s prescribing information and must be individualized for each patient.

Safety data for bupivacaine hydrochloride in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made by the treating physician in consultation with the patient.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Bupivacaine provides a longer duration of action compared with agents such as lidocaine or mepivacaine, making it suitable for procedures requiring extended anesthesia. However, its higher potency also carries a greater risk of cardiotoxicity, so careful dosing and monitoring are essential.

Marcaine Glucose should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from direct light, moisture, and extreme temperature fluctuations to maintain stability and sterility.

The product is administered by a qualified healthcare professional via infiltration, intrathecal injection, or peripheral nerve block. Proper aseptic technique, correct needle placement, and aspiration before injection are essential to avoid intravascular administration and systemic toxicity.

Serious risks include cardiac arrhythmias, seizures, severe hypotension, and allergic reactions such as anaphylaxis. Early recognition of systemic toxicity signs and immediate supportive measures are critical to prevent life‑threatening complications.

Patients with known hypersensitivity to bupivacaine or other amide‑type local anesthetics, those with significant cardiac conduction abnormalities, uncontrolled severe hypotension, or who are receiving contraindicated interacting medications should not receive Marcaine Glucose.